Sterling Pharma and MIB partner to develop low-cost route to new oral COVID drug
The new route uses a novel enzyme, cytidine aminotransferase, which would reduce the manufacturing cost of the drug
Global CDMO Sterling Pharma Solutions and the University of Manchester Institute of Biotechnology (MIB) have formed a partnership to support the development of a novel, low-cost manufacturing route to molnupiravir — a new antiviral drug for the treatment of COVID-19.
From its facility in Dudley, Northumberland, the CDMO will provide chemical scale-up to multi-kilogrammes and process development services for Manchester University's project for which it has received grant funding from the Bill and Melinda Gates Foundation.
Although the drug was was originally developed by Ridgeback Biotherapeutics and Merck Sharp and Dohm, the new route has been developed by researchers at MIB, and includes the use of a novel enzyme, cytidine aminotransferase, which would reduce the manufacturing cost of the drug.
The process could allow generic pharmaceutical manufacturers to produce large-scale quantities of molnupiravir to supply of lower-income countries, subject to authorisation from further regulatory agencies, including the World Health Organization and national governments.
Molnupiravir, which has recently (4 November 2021) been approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of patients with COVID-19, is the first oral antiviral treatment for coronavirus that could be self-administered at home.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance